NCT00858754

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Bausch Health Americas, Inc. · Industry
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This purpose of this study is to evaluate the safety and effectiveness of a subcutaneous (injection beneath the skin) form of methylnaltrexone in subjects who have cancer-related pain and constipation from taking opioids. The length of participation will be up to 7 weeks.

Conditions

• Opioid-Induced Constipation

Interventions

Type	Name	Description
DRUG	methylnaltrexone
DRUG	placebo

Timeline

• Start date: 2009-03-01
• Primary completion: 2009-08-01
• Completion: 2009-08-01
• First posted: 2009-03-10
• Last updated: 2019-11-29

Locations

8 sites across 4 countries: United States, Canada, France, Spain